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Abstract: Many studies have shown evidence in support of the beneficial effects of phytochemicals
in preventing chronic diseases, including cancer. Among such phytochemicals, sulphur‐containing
compounds (e.g., isothiocyanates (ITCs)) have raised scientific interest by exerting unique chemo‐
preventive properties against cancer pathogenesis. ITCs are the major biologically active
compounds capable of mediating the anticancer effect of cruciferous vegetables. Recently, many
studies have shown that a higher intake of cruciferous vegetables is associated with reduced risk of
developing various forms of cancers primarily due to a plurality of effects, including (i) metabolic
activation and detoxification, (ii) inflammation, (iii) angiogenesis, (iv) metastasis and (v) regulation
of the epigenetic machinery. In the context of human malignant melanoma, a number of studies
suggest that ITCs can cause cell cycle growth arrest and also induce apoptosis in human malignant
melanoma cells. On such basis, ITCs could serve as promising chemo‐therapeutic agents that could
be used in the clinical setting to potentiate the efficacy of existing therapies.
Keywords: isothiocyanates; glucosinolates; chemo‐therapy; cruciferous vegetables; skin cancer;
malignant melanoma; cell cycle; growth arrest

1. Introduction
Nutrition is known to play an important role in human health, primarily in the context of
preventing chronic disease development including cancer. As such, it can have a positive impact in
health outcomes, thus improving quality of life [1,2]. Overall, the protective role from consuming
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plant‐derived foods has been documented and well established in numerous studies. In particular,
the potential of fruits and vegetables in disease prevention was documented in the case of
phytochemicals, the bioactive components of plant‐derived foods capable of exhibiting a wide range
of biological activities including anti‐inflammatory, anti‐infectious, anti‐oxidant and anti‐cancer [3–
7]. Furthermore, evidence also shows that these compounds can modulate gene expression through
epigenetic mechanisms involving DNA methylation, histone modification and modulation of
miRNAs [8,9]. However, their prevailing anti‐oxidant capacity is of particular importance given that
oxidative stress (and, consequently, accumulation of free radicals) plays a major role in ageing and
other chronic diseases, including heart disease, cognitive disorders and cancer. Briefly, an imbalance
in the equilibrium of antioxidants and free radicals (of oxygen and/or nitrogen species) can result in
DNA damage and genomic instability, thus increasing the risk for disease development and mortality
[10–13]. To these ends, phytochemicals have been shown to contribute to the detoxification of the
body and thus have a positive impact on human health and disease prevention [13–15]. In the context
of cancer chemo‐therapy, the use of agents (synthetic, natural or biological) is utilized in order to
reverse, suppress or prevent the multi‐stage process of carcinogenesis [16,17]. On the other hand,
natural products possess pleiotropic mechanisms responsible for their health benefits, including
prevention of cancer development [7,14,15]. Phytochemicals are generally categorized according to
their chemical properties and functional groups into carotenoids, phenolics, nitrogen‐containing
(e.g., alkaloids, amines) and organosulfur compounds (e.g., isothiocyanates and allyl sulphides such
as allicin) [18]. Especially, sulfur‐containing substances (isothiocyanates (ITCs)) have raised scientific
interest with their unique properties in cancer prevention and treatment.
Glucosinolates (GLs) are an important group of phytochemicals abundant in vegetables of the
Brassicaceae family, including broccoli, watercress, brussels sprouts, cabbage, horseradish,
cauliflower, mustard, etc. [19]. They all share a common core structure consisting of a β‐
thioglucosilated moiety linked to a sulfonated aldoxime and a variable aglucone side chain (R),
derived from eight selected amino acids (alanine, leucine, isoleucine, valine, phenylalanine, tyrosine,
tryptophan and methionine and possibly glutamic acid) [20,21]. According to the amino acid
precursors used at the early stages of their biosynthesis, they are mainly categorized as aliphatic,
aromatic, heterocyclic (indoles), benzoate, multiple glycosylated and sulfur‐containing GLs [22,23].
Their content and type in plants vary between and within the family members [23]. It is mainly
dependant on environmental factors like cultivation, climate, region, genotype, the part of the plant
and its developmental stage [24–27]. To date, about 130 different GL structures have been identified
[28]. However, a more detailed review of the literature led to the characterization of a greater number
of structures, thus it is currently considered that the number reaches 200 individual structures [23].
Upon hydrolysis, they give rise to various bioactive compounds, including ITCs, responsible for the
health benefits provided through the consumption of these cruciferous vegetables [29,30]. ITCs are
compounds characterised by an R–N=C=S structure, where R is a variable side chain consisting of
alkyl or allyl groups. They are highly reactive electrophiles that interact reversibly with the thiol
group of cystine residues to form dithiocarbamates [31].
In general, ITCs are mainly responsible for the flavour and odour of cruciferous vegetables and
exert a wide range of bioactivities from defence against pathogens (in Brassica vegetables) for the
prevention of cancer development [32]. Among them, their anti‐microbial, anti‐oxidant and anti‐
inflammatory properties are of particular importance. More specifically, the anti‐microbial activity
of ITCs has been documented in a number of studies, suggesting possible use of these compounds as
natural antibiotic agents, food additives and/or pesticides [33–39]. It has been reported that they have
both bacteriostatic and bactericidal potencies and many mechanisms have been suggested to mediate
these properties. Briefly, ITCs exert anti‐microbial activities through disruption of the cell membrane,
deregulation of enzymatic processes and induction of heat‐shock proteins as well as oxidative stress
[33]. In addition, ITCs can also act as indirect antioxidants by activating the Nrf2‐dependent pathway
[40,41]. To this end, a study by McWalter et al., 2004 has shown that ITCs increased the expression of
detoxifying enzymes in both wild‐type mice and mouse cell lines, but not in Nrf2‐knockdown ones
[42]. Moreover, a microarray‐based expression profile analysis revealed Nrf2‐mediated elevation of
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antioxidant proteins and metabolizing enzymes in hepatocellular carcinoma (HepG2) cells treated
with wasabi‐derived sulforaphane (SFN) and SFN analogues, highlighting the importance of this
pathway in inducing an antioxidant response [43]. However, a constitutive activation of this pathway
could be potentially advantageous for cancer cells by creating an environment that favours cell
survival and growth. In addition, the persistent Nrf2 activity can interfere with the metabolic process
of some anti‐cancer drugs, leading to chemo‐resistance [44–46]. Overall, it seems that although
ectopic expression of Nrf2 could be detrimental in fully‐developed cancers, its transient activation in
healthy individuals can exert a protective effect [47].
Apart from its role in anti‐oxidant processes, Nrf2 can also mediate an anti‐inflammatory
response through the transcriptional factor nuclear factor‐kappa B (NF‐κB) signalling pathway,
although the exact mechanism has not yet been elucidated [48–50]. On another note, ITCs can also
repress the inflammatory process by inhibiting NF‐kB which, in turn, regulates the expression of pro‐
inflammatory and anti‐apoptotic proteins [51–53]. Moreover, other mechanisms (independent of
Nrf2/NF‐kB) have also been shown to mediate ITC‐induced anti‐inflammatory properties including
epigenetic alterations [54,55]. For example, it has been shown that SFN suppresses histone
deacetylase (HDAC) activity while increasing DNA methyltransferase 1 (DNMT1) expression, thus
blocking lipopolysaccharide (LPS)‐induced pro‐inflammatory cytokine formation in porcine
monocyte‐derived dendritic cells [55]. Another novel anti‐inflammatory role of SFN has been
proposed recently, showing that it inhibits the formation of multiple inflammasomes and thus
showing an action against inflammasome‐originated diseases [56]. Finally, another mechanism
involves the binding to the nucleophilic N‐terminal proline residue of the macrophage migration
inhibitory factor (MIF), thus modifying its structure and preventing its interaction with extracellular
receptors and other protein targets. MIF is a pro‐inflammatory cytokine with pro‐tumourigenic, pro‐
angiogenic and anti‐apoptotic properties. As such, it is involved in various inflammatory diseases,
like rheumatoid arthritis and atherosclerosis, in addition to being implicated at different stages of
tumour development, including proliferation and angiogenesis [57–59]. Consequently, a number of
studies have supported the role of ITCs, especially sulforaphane (SFN), iberin (IBN), allyl‐ITC (AITC),
benzyl‐ITC (BITC) and phenethyl‐ITC (PEITC) (Figure 1), in cancer prevention and chemotherapy
[60–64], topics which will be discussed in more detail below.

Figure 1. The structures of major isothiocyanates (ITCs).
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1.1. GLs‐Myrosinase System
GL hydrolysis is catalysed by an enzyme called myrosinase, which was discovered in 1839 by
Bussy as a protein necessary for the release of essential oil from mustard seed [65]. Disruption of the
plant by chewing or cutting leads to the release of myrosinase, a β‐thioglucosidase, and brings it into
contact with their substrates where it breaks down the sulfur group of the glucosidic bond [21,66]. It
is mainly considered to be located in idioblastic cells (as opposed to GLs which are located in different
cells inside the plant), although more studies are needed to elucidate their compartmentalization
within plants [67]. For instance, in the model species Arapidopsis thaliana, GLs were found in S‐cells
(located between the phloem and the endoderm), which are in close proximity to myrosin cells
(located at the phloem parenchyma) [67–69]. This compartmentalization acts as a barrier that allows
GLs to degrade only when the plant is under stress conditions, such as during a pathogen attack or
tissue disruption. Activation of the myrosinase–glucosinolate system (also known as mustard oil
bomb) results in the formation of diverse chemically and biologically distinct compounds including
thiocyanates, isothiocyanates, nitriles and indoles [32,70,71] (Figure 2). Usually, a ‘Lossen’‐like
rearrangement occurs that promotes formation of ITCs [21,71–73]. At the end of this process, the
outcome is largely dependent on various other factors like pH, temperature and availability of ferrous
ions, epithiospecifier proteins (ESP), presence of proteins that interact with myrosinase as well as
type of GLs [70,74,75]. Other factors that affect the content of GLs (and, consequently, their
concentration and intake) include food processing, cultivation, storage and post‐harvest processing
[76–79]. Moreover, lower ITC levels can be produced by other mechanisms, including hydrolysis of
GLs by bacterial myrosinases. For example, in humans, after consumption of cooked vegetables the
formation of ITCs is promoted by the microbiome in the intestinal tract after destruction of
endogenous myrosinase due to food preparation; however, this process is poor, resulting in a much
lower yield of ITCs [71,80]. Once ITCs are formed in the gut, they enter the cell passively where they
bind with high affinity and reversibly to glutathione (GSH) leading to their metabolism (and
consequently elimination) through the mercapturic acid pathway. Briefly, ITCs are diffused into the
blood circulation through the gastrointestinal tract where they conjugate with GSH, a reversible
reaction catalyzed by glutathione S‐transferases (GSTs). Enzymatic modifications of the GSH moiety
take place in the liver with the final N‐acetylcysteine‐(NAC‐)conjugate being produced in the
kidneys, where it is actively secreted into the urine [31,66,70,81].

Figure 2. Hydrolysis of glucosinolates by myrosinase.

1.2. Anti‐Cancer Properties
ITCs exert their anti‐tumour activities through various mechanisms, including (i) modulation of
phase I and II enzymes, (ii) inhibition of cell growth by causing cell cycle arrest and inducing cell

Antioxidants 2019, 8, 106

5 of 32

death, (iii) prevention of metastasis and angiogenesis and (iv) regulation of the epigenetic machinery
(Figure 3).

Figure 3. Schematic representation of the proposed molecular pathways targeted by isothiocyanates
(ITCs), glutathione (GSH), uridine 5′‐diphospho‐glucuronosyltransferase (UDPG), quinone reductase
(QR).

1.2.1. Inhibition of Phase I and Induction of Phase II Enzymes
Phase I and II enzymes are important mediators of the detoxification process in the human body.
They interact with various chemicals, such as toxins and carcinogens, playing an important role in
their metabolism and excretion from the body. Cytochrome P450 (CYP450) enzymes are the most
important phase I enzymes, which either deactivate or, in some cases, activate pro‐carcinogens to
their active form. On the other hand, phase II enzymes exert a predominantly protective role as their
interaction with carcinogens increase their elimination from the body. The most important phase II
enzymes are glutathione S‐transferases (GSTs), uridine 5′‐diphospho‐glucuronosyltransferase
(UDP)‐glucuronosyl transferase, nicotinamide adenine dinucleotide phosphate (NADPH), quinine
reductases and glutamate cysteine ligase. In general, it is proposed that ITCs downregulate phase I
enzymes to inhibit carcinogen activation, while upregulating phase II enzymes to enhance
detoxification and prevent reactive oxygen species (ROS)‐induced damage [82,83]. SFN (3 mg/kg and
12 mg/kg) has been shown to regulate the activity of CYP2B, CYP3A2 and CYP1A2 enzymes and
induce the expression of quinone and glutathione reductase in rats [84]. In line, PEITC (150 μmol/kg)
increases the expression of UDP‐glucuronosyltransferase UGT1A6 (uridine diphosphate
glucuronosyltransferase 1 family, polypeptide A6) and also modulates CYP2B15 activity while
decreases nicotinamide N‐methyltransferase (NNMT) levels in rats [85]. Both BITC and PEITC were
found to prevent nicotine (BITC and PEITC at 25 μM and 3 μM respectively) and tobacco‐specific
nitrosamine 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone (NNK) (BITC and PEITC at 1 μM and
0.3 μM, respectively) metabolism by inhibiting the activation of CYP2A6 and CYP2A13, respectively,
in an NADPH‐dependent manner [86]. Moreover, SFN (10 μM) increased the activity of various GSTs
(A3, A4, M1, P1 and T1) in order to inactivate aflatoxin B1‐8,9‐epoxide (AFBO) in alpha mouse liver
12 (AML12) cells [87]. Oral administration of allyl isothiocyanate (AITC) (40 μmol/kg/day) also
increased the activity of both quinone reductase (QR) and GSTs in urinary bladder, thus indicating a
reduced risk of bladder cancer after frequent exposure to ITCs [88]. Exposure of primary normal
human bronchial epithelial cells (NHBE) and lung adenocarcinoma cells (A549) to both broccoli
sprout extracts as well as individual ITCs (e.g., SFN, BITC and PEITC) have led to upregulation of
GSTP1 (Glutathione S‐transferase P) and NQO1 (NAD(P)H dehydrogenase [quinone] 1) phase II
enzymes [89]. In addition, SFN, ECN (erucin) and IBN (1‐12 μM) were also found to increase the
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expression levels of thioredoxin reductase 1 (TrxR1) in human breast cancer (MCF‐7) cells [90].
Furthermore, SFN also increased the transcription of UDP‐glucuronosyl transferase (UGT) 1A1 as
well as glutathione S‐transferase A1 (GSTA1) in human hepatoma HepG2 and HT29 cells in a time‐
and dose‐dependent manner [91].
1.2.2. Cell Cycle Arrest and Cell Death
The cell cycle consists of four distinct phases: G1, S, G2 and M. Cells go from a resting phase
(G0) to proliferation and back to rest. The progression from one phase to the next is mainly regulated
by cyclins that form complexes with cyclin‐dependent kinases (CDKs) and is inhibited by CDK
inhibitors (including p21 and p27) which have a broad affinity for various CDKs. All of these are
found deregulated in cancer, thus leading to uncontrolled proliferation of cancer cells [92]. ITCs have
been found to induce cell cycle arrest by modulating the expression levels of cell cycle regulators
including cyclins and CDKs. Exposure of human colon carcinoma (HT29) cells to SFN (15 μM) was
shown to increase the accumulation of these cells in the G2/M phase through activation of p21 and
cdc2 kinase [93]. A study by Cheng et al., 2016 showed an induced growth arrest in the G2/M phase
by inhibiting the expression of Cyclin B1 and disruption of cyclin B1/CDC2 conjugate in cervical
cancer cells exposed to SFN (6.25 μM, 12.5 μM and 25 μM) [94]. Alternatively, cell cycle arrest (in
G0/G1 phase) and apoptotic induction were observed in T24 bladder cancer cells exposed to SFN (5‐
20 μM), an effect that was mediated by overexpression of a p27 cyclin‐dependent kinase inhibitor
[95]. Inhibition of growth (at the G0/G1 phase) through modulation of p53, p21, p17, CDK2 and cyclin
E activities was also observed in HSC‐3 oral carcinoma cells after exposure to PEITC (0.5, 1, 2, 2.5 and
5 μM) [96]. Cyclin B1, as well as Cdk1, Cdc25B and Cdc25C, expression levels were found to be
dramatically decreased in AITC‐treated (20 μM) prostate cancer cells with a resultant increase in the
number of cells in the G2/M phase [97]. In addition, BITC also induced G2/M phase arrest in human
pancreatic cancer (Capan‐2) [98] and HL‐60 cells [99], at concentrations of 20 μM and 5 μM
respectively, by upregulating p21 and also modulating the expression of other regulatory proteins
important for cell cycle progression. Moreover, a study by Cheung et al., 2008 assessed the
involvement of the p38/MAPK (mitogen‐activated protein kinases) pathway in ITC‐induced growth
suppression. In this work, treatment of HT29 colon cancer cells with an inhibitor specific for p38
activity attenuated the PEITC‐induced (25 μM) G1 arrest, while MAPK activation induced the activity
of various other cyclins and, consequently, blocked growth progression [100]. Other studies have also
shown that ITCs induced cell cycle arrest in various cancer cell lines, an effect associated mainly with
the regulation of the expression levels of p21, GADD45 (growth arrest and DNA damage) and various
other cyclins [101–104]. Finally, only recently, it was proposed that the deregulation of the cell cycle
may gradually lead to apoptotic induction [93].
1.2.3. Apoptosis
Apoptosis is a genetically programmed cell death which is characterized by cell shrinkage,
chromatin condensation, DNA fragmentation and formation of apoptotic bodies. The apoptotic
process is complex and is regulated by a wide range of proteins including (but not limited to) various
caspases, B cell lymphoma 2‐family (Bcl2) proteins and the p53 gene. The apoptotic process is
deregulated in cancer cells (thus overcoming cell death) and so compounds that can target the
induction of molecules involved in the apoptotic process could be of potential benefit as therapeutic
agents [105,106]. ITCs have been shown to trigger cell death in cancer cells and their role in apoptotic
induction has been excessively studied. The mode of action is complex and it seems that there is a
cross‐talk between signalling pathways that regulate the transcription of various proteins important
for the apoptotic process [62,107,108]. A study by Yu et al., 1998 showed that exposure of human
cervical cancer (HeLa) cells to PEITC (and other structurally related ITCs) (10 μM) induced apoptosis,
while treatment of these cells with a caspase‐3 inhibitor attenuated this phenomenon, thus suggesting
that the apoptotic process is strongly linked with caspase‐3 activity [109]. To date, many more studies
have shown that ITCs exert their anti‐proliferative effect through diverse regulatory pathways
including: (i) Various signal transduction pathways (PI3K/AKT, MAPKs and mTOR (mammalian
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target of rapamycin) [110,111], (ii) increased production of reactive oxygen species (ROS) [112], (iii)
inhibition of heat‐shock proteins [113] and (iv) mitochondrial dysfunction [96,108,114]. In another
study, Xu et al., 2006 showed that treatment of prostate cancer (PC‐3) cells with SFN (5–40 μM), PEITC
(2–10 μM) and AITC (5–100 μM) decreased cell viability by inducing apoptosis. More specifically,
ERK1/2 (extracellular signal‐regulated kinases), JNK1/2 (c‐Jun N‐terminal kinases), Elk‐1 (ETS‐like
gene 1, tyrosine kinase) and c‐Jun phosphorylation levels were significantly increased, resulting in
the induction of activator protein 1 (AP‐1), which plays an important role in various processes
including cell death [115]. The contribution of EGFR (epidermal growth factor receptor)/PI3K
(phosphoinositide 3‐kinase)/AKT (protein kinase B) and MAPK pathways in ITC‐induced apoptosis
and cell cycle growth arrest was also documented in a number of other studies, suggesting the
importance of these pathways in ITC‐induced cytotoxicity [110,116–119]. On the other hand,
modulation in the activity levels of pro‐apoptotic (e.g., Bax, Bid and Bak) and anti‐apoptotic (e.g.,
Bcl2 and Bcl‐XL) proteins, as well as various other caspases, has been also involved in ITC‐induced
cell death. Treatment of pancreatic cancer cells with PEITC (2.5 μM, 5 μM and 10 μM) increased
protein levels of Bak while decreased those of Bcl2 and Bcl‐XL thus inducing apoptosis [120]. In
addition, exposure of Jurkat T‐leukaemia cells at 30 μM of SFN, resulted in increased Bax and p53
expression levels, which were correlated with an apoptotic induction [121]. Moreover, AITC‐induced
apoptosis (7.5 μM, 15 μM and 30 μM) was also found to be dependent on elevated levels of Bax
together with decreased levels of Bcl2 in renal carcinoma cells [122].
1.2.4. Oxidative Stress
A number of studies also support that ITCs can inhibit cell survival through increased
production of reactive oxygen species (ROS). To this end, high concentrations of SFN (10 μM and 20
μM) significantly induced ROS generation in the p53‐null osteosarcoma (MG‐63) cell line by reducing
GSH production and recycling, thus contributing to dysfunction of membrane potential and
decreased cell survival. It is noteworthy that, although SFN is a well‐known antioxidant agent, under
this experimental setting, an imbalance between the antioxidant and prooxidant activities was
observed, with the antioxidant activity being dependant on the concentration and exposure period
of MG‐63 cells to SFN [112]. Also, 10 μM of SFN triggered the intracellular accumulation of ROS,
resulting in significantly increased levels of Nrf2 as well as heme oxygenase‐1 (HO‐1), and
consequently, decreased cell survival of bronchial epithelial cells. Pre‐treatment with N‐
acetylcysteine (NAC) suppressed SFN‐induced elevation of Nrf2 and HO‐1 levels, suggesting that
the observed effect was dependent on the oxidative stress response [123]. In line with these
observations, exposure of oral cancer cells to BITC, (7.5 μM) and PEITC (10 μM) also caused increased
production of oxidative stress leading to GSH depletion, increased expression of serine/threonine
protein kinase ATM, Chk2, p53, and p21, while expression of Cdc2, cyclin B1, Mcl‐1 and Bcl‐2 was
suppressed. Thus, ROS elevation resulted in DNA damage, mitochondria disruption and,
subsequently, induction of cell cycle growth arrest and apoptosis [124,125].
Another mechanism accounting for ITC‐induced inhibition of cell proliferation and survival,
through elevation of ROS levels, involves the downregulation of specificity protein (Sp) transcription
factors and their gene targets. These transcription factors regulate the expression of various genes
involved in proliferation, survival, angiogenesis, inflammation and drug resistance. Overexpression
of these proteins is a common finding in multiple cancer types and is associated with poor patient
prognosis [126–128]. The importance of Sp downregulation has been demonstrated in a recent study
where knocking‐down Sp1, Sp3 and Sp4 in breast, kidney, pancreatic, lung and colon cancer cell lines
reduced cancer cell growth, promoted apoptosis and prevented cell migration and invasion [129].
Recently, BITC and PEITC have been reported to trigger oxidative stress and inhibit proliferation in
cancer cells, through a ROS‐dependent mechanism that involves the downregulation of Sps [130,131].
These observations are consistent with other studies utilizing ROS‐inducing agents with anti‐cancer
properties such as celastrol [132], HDAC inhibitors [133], penfluridol [134], piperlogumine [135],
curcumin and other curcuminoids [136,137], CDDO‐Me (a synthetic derivative of triterpenoid
glycyrrhetinic acid) [138,139] and GT‐094 (a nitric oxide‐non‐steroidal anti‐inflammatory drug) [140].
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Their mechanism of action is thought to be ROS‐dependent, since their effects are abrogated in the
presence of GSH, and involves decreased expression of Sps via modulation of the Myc‐miR‐ZBTB
axis. More specifically, it is proposed that ROS induction inhibits the expression of Myc and Myc‐
associated micro‐RNAs (e.g., miR‐27a, miR‐20a and miR‐17‐5p) and, consequently, the activation of
zing finger and BTB (ZBTB) inhibitors, thus downregulating Sp transcription factors and their targets
[126,141]. Overall, it appears that ITCs can modulate the expression of genes in more than one cellular
pathway, important for cell proliferation and survival.
1.2.5. Autophagy
Autophagy is an essential process for cell survival and maintenance through which cells degrade
their damaged and defective cytoplasmic components. It occurs when cells are exposed to several
stress stimuli, such as low oxygen, starvation and accumulation of faulty organelles and proteins,
among others. In general, under ‘housekeeping levels’, autophagy promotes cell survival and growth
by removing defective and redundant cellular constituents. However, under conditions of
diminished apoptosis or induction of high levels of autophagy, it may also promote cell death, either
through self‐cannibalization or by inducing apoptosis [142,143]. In the context of carcinogenesis,
autophagy can play a dual role either as (i) a tumour‐suppressor mechanism by scavenging mutated
proteins and faulty organelles (thus inhibiting cell transformation), or (ii) as a tumour‐progression
mechanism by favouring cancer cell survival and proliferation under hypoxic conditions. Given that
autophagy is essential in cellular transformation, the discover of agents capable of inhibiting its
induction could be of particular importance in cancer therapy [144,145]. Alternatively, its ectopic
activation in cancer cells could also serve as a pro‐death signal. To this end, other studies have shown
that its induction can inhibit cancer cell growth through activation of T cell‐dependent immune
responses [146,147].
ITCs can act as autophagic inducers and, by doing so, they may exert either a protective role
[148–157] or promote cell death [158–162] according to tumour type, stage and genetic context. To
this end, a recent study investigated the autophagic involvement on BITC‐induced inhibition of cell
growth in lung cancer cells and showed an induction of ER (endoplasmatic reticulum) stress‐
mediated autophagy capable of protecting from the suppressive effects of BITC on cancer cell growth.
Pre‐treatment of cells with an autophagic inhibitor enhanced the growth inhibitory effect of BITC,
supporting the cytoprotective role of autophagic induction [149]. In line with these observations,
exposure of prostate cancer cells to BITC also triggered autophagy through mTOR signaling
inhibition [150] or ROS‐accumulation [151]. Inhibition of autophagy in these experimental models
found to enhance BITC‐induced apoptosis of prostate cancer cells. Moreover, PEITC anti‐metastatic
potential reported to be significantly increased after inhibition of autophagy and, subsequently,
inactivation of the JAK2 (Janus kinase 2)/STAT3 (signal transducer and activator of transcription 3)
pathway in three lung cancer cell lines [152]. In contrast, breast cancer cells exposed to BITC are
reported to promote autophagic cell death through increased expression of the FOXO1 (forkhead box
protein O1) pathway [158]. Also, exposure of prostate cancer cells to PEITC resulted in increased cell
death via Atg5‐mediated induction of autophagy and apoptosis. In this experimental setting, the
apoptotic induction was attenuated after pharmacological inhibition of autophagy [159]. In line, SFN‐
NAC (sulforaphane‐N‐acetyl‐cysteine), an important metabolite of SFN, was shown to downregulate
α‐tubulin through induction of autophagy and activation of ERK1/2, leading to cell‐cycle arrest and
cell growth inhibition in glioma cells [160].
1.2.6. Epigenetic Mechanisms
ITCs can also exert their anti‐tumourigenic properties by interfering with the epigenetic
machinery [61], which plays an important role in a number of physiological (e.g., genomic imprinting
genomic imprinting [163–165], X‐chromosome inactivation [166,167], development of the embryo
and placenta [168–170]) as well as disease‐modulating processes, including carcinogenesis [171–173].
Within the context of carcinogenesis, changes in DNA methylation patterns, as well as post‐
translational modifications in histone proteins, result in repressed transcription (i.e., silencing) of
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tumour suppressor genes and/or activation of proto‐oncogenes to oncogenes, among other
mechanisms [174–176].
1.2.6.1. Inhibition of HDACs
Histone deacetylases (HDACs) are generally associated with condensed chromatin
conformation leading to transcriptional repression. To date, HDAC inhibitors have been utilized in
the clinical setting and are considered to be therapeutic agents against tumour progression by causing
cell cycle arrest, inducing cell death and inhibiting angiogenesis [177,178]. To this end, ITCs have
been shown to act as potent HDAC inhibitors in various cancer cell lines by inducing genomic
alterations resulting in changes in carcinogenic activity of xenobiotics through (i) Nrf2‐mediated
induction of phase II detoxification enzymes, (ii) induction of cell cycle growth arrest and iii)
apoptosis [179–182]. More specifically, PEITC (10 μM) was shown to cause cell cycle arrest of prostate
cancer cells (LNCaP) by enhancing Histone 3 (H3) acetylation which was shown by chromatin
immunoprecipitation (ChIP) to be associated with increased expression of p21, thus suggesting the
inhibition of HDACs [182]. In addition, SFN (at 15 μM) was also found to be an efficient HDAC
inhibitor in BPH‐1 (benign prostatic hyperplasia), LnCaP (lymph node carcinoma of the prostate) and
PC‐3 (prostate epithelial) cells by triggering growth arrest and apoptotic processes [183]. Also, protein
expression and activity levels of HDACs 1, 2 and 3 were shown to be significantly decreased in a
number of cancer cells exposed to ITCs [184–186]. Phenylhexyl ITC (PHI), at concentrations between
1–20 μM, was found to significantly reduce HDAC1 and HDAC 2 activity, in prostate cancer cells, as
well as to enhance the acetylation of histones H3, H4 and H3 lysine [186]. SFN, at 15 μM, prevented
the repair of DNA damage in human colon cancer (HCT116) cells via diminished HDAC activity
levels, accompanied with a marked reduction on the expression of HDACs 3 and 6, resulting in
decreased C‐terminal‐binding protein (CtBP)‐interacting protein (CtIP) levels, an important mediator
of DNA repair capacity, thus inducing cell cycle arrest and apoptosis [180]. Furthermore, SFN
decreased HDAC activity, which led to increased p21 and Bax protein expression levels and induced
growth arrest in the G2/M phase and apoptosis in murine melanoma (B16) (concentrations ranging
between 3–12 μM), human glioma (U251) (12 μM) [179] and human lung cancer (A549) (15 μM) cells
[187]. A study by Jiang et al., 2016 also showed reduction of tumour growth in the lungs of mice
exposed to SFN through inhibition of HDAC activity [187]. Other studies also supported the
inhibitory effect of ITCs in HDAC activity in both pancreatic [185] and bladder [184] cancer cells. On
the other hand, exposure of human pancreatic cancer cells, at 10 μM of BITC, inhibited
HDAC1/HDAC3 activity, leading to inactivation of NF‐kB and cyclin D1, in vivo and in vitro, thus
leading to growth arrest of these cells [185]. Moreover, SFN and erucin (ECN), at 20 μM, attenuated
the phosphorylation of Histone 1 isoforms, an important step in bladder cancer development through
inactivation of HDACs 1, 2, 4 and 6 [184].
Interestingly, a study by Myzac et al., 2004 was the first to report on the inhibitory effect of SFN
on HDACs [188]. In fact, in this study, it was documented that two conjugated compounds of SFN
metabolism [SFN‐Cys (cysteine)and SFN‐NAC (N‐acetylcysteine conjugate)] were responsible for the
inhibition of HDAC activity and not the parent compound itself. This observation was confirmed by
pre‐treating cells with a GST inhibitor, thus impairing the first step of the mercapturic acid metabolic
pathway of SFN and consequently the production of its major metabolites. Also, treatment of cells
with SFN, SFN‐GSH, SFN‐Cys or SFN‐NAC showed that only the two metabolites could effectively
inhibit HDACs, while SFN and SFN‐GSH had no significant inhibitory activity in vitro [188]. Between
the two metabolites, SFN‐Cys was found to be the more potent inhibitor. In fact, the order of such
inhibition efficiency was documented to be as follows: SFN = SFN–GSH < SFN–NAC < SFN–Cys.
Furthermore, by utilizing molecular modeling methodologies, it was revealed that SFN–Cys’s
inhibitory capacity was via direct interaction with HDACs, suggesting its potential role as a
competitive inhibitor. To this end, it was shown that the α‐amino group of SFN–Cys fits into the
enzyme pocket and its carboxylate group creates a ligand with the zinc atom within the active site of
the ezyme [188,189]. These insights into how SFN‐conjugates bind and consequently suppress
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HDACs have led to the identification of other structurally related ITCs like sulforaphene,
phenylbutyl isothiocyanate, phenethyl isothiocyanate and erucin, among others [189,190].
1.2.6.2. Inhibition of DNMTs
DNA methylation results in the addition of methyl groups in cytosine residues of CpG
dinucleotide regions that are dispersed across the genome [191,192]. The transfer of these methyl
groups is utilized by DNA methyltransferases (DNMTs) with the most important ones being DNMTs
1, 3A and 3B [193,194]. Both hypo‐ and hyper‐methylation have been observed to enhance the
expression of oncogenes while inhibiting that of tumour suppressor genes, respectively [195]. ITCs
have been shown to cause changes in DNMT expression patterns, thus leading to differential
expression of genes capable of mediating the carcinogenic process [196].
In prostate cancer cells, SFN suppressed the expression of DNMT1 and DNMT3A thus
decreasing cell proliferation [197,198]. To this end, it has been proposed that SFN‐induced inhibition
of DNMT1 is associated with HDAC suppression, which can lead to decreased histone deacetylation
leading to re‐expression of p21 and impairment of DNMT1 activation [196]. Phenylhexyl
isothiocyanate (PHI) (ranging between 5 and 40 μM) was also found to reduce the activity of DNMT1
and 3B (thus causing the re‐expression of the p15 tumour suppressor gene), in addition to causing an
increased acetylation of histones H3 and H4 in leukaemic T cells [199]. In general, it has been
demonstrated that ITCs are epigenetic agents with dual activity on the epigenome, by inhibiting both
DNA hyper‐methylation and histone deacetylation [181,200,201]. To this end, SFN at 2.5 μM and 5
μM has been shown to induce Nrf2‐dependent inhibition of skin tumour transformation in mouse
JB6 cells by decreasing the expression of DNMT1, DNMT3A and DNMT3B, as well as that of HDACs
1, 2, 3 and 4 [181]. Similarly, SFN at 1 μM and 2.5 μM, decreased Nrf2 promoter methylation and
histone deacetylation, both events leading to an increase in N‐ribosyldihydronicotinamide quinone
reductase (NQO)‐1 transcription in prostate cancer cells [200]. SFN‐treated human breast cancer cells
(5 μM and 10 μM) underwent apoptosis mediated by downregulating the expression and activity of
DNMT1 and DNMT3A, thereby repressing the activation of the human telomerase reverse
transcriptase (hTERT) gene commonly overexpressed in many cancers [202]. On the other hand, in
estrogen receptor (ER)‐negative breast cancer cells exposed to 10 μM of SFN‐suppressed protein,
expression levels of HDACs and DNMTs both contributed to decreased cell viability, suggesting its
usage as a therapeutic agent for the treatment of patients with ER‐negative breast cancer [201].
Finally, Ras‐association domain family 1 isoform A (RASSF1A) is a tumour suppressor gene found
downregulated in a number of cancers. Exposure to 5 μM PEITC restored RASSF1A expression levels
and decreased viability levels by inhibiting the activity levels of DNMT1 DNMT3A and DNMT3B, as
well as those of HDACs 1, 2, 4 and 6 [203].
1.2.6.3. Modulation of miRNAs
mi‐RNAs are functional non‐coding RNAs 20–24 nucleotides long that play a critical role in
regulating various physiological processes; they are also implicated in disease development,
including cancer. Various mi‐RNAs such as miR‐155 and miR‐21 are deregulated during
carcinogenesis, promoting tumour development and progression [204]. Many studies have shown
that ITCs exert their effect by regulating the epigenetic machinery through targeting of specific
miRNAs in cancer. For instance, when epithelial colon (NCM460 and NCM356) cell lines were
exposed to 10 μM SFN and IBN, upregulation of miR‐23b, miR‐27b (tumour suppressors) together
with downregulation of miR‐155 were evident, thus suggesting their contribution in chemo‐
prevention [205]. Prostate cancer (PC3) cells exposed to 2.5 μM PEITC overexpress miR‐194, which
decreases expression of matrix metalloproteinases (MMPs) and blocks the invasion capacity of these
cells [206]. In non‐small cell lung cancer (NSCLC), miR‐616‐5p is overexpressed and, consequently,
promotes tumour progression and metastasis. In this experimental setting, exposure to 5 μM SFN
inhibits growth and migration of non‐small cell lung cancer cells by downregulating miR‐616‐5p
[207]. Moreover, combinational treatment of SFN with temozolomide (TMZ) enhanced TMZ’s
potential for apoptotic induction by suppressing miR‐21 expression [208]. In bladder cancer cells,
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epithelial‐to‐mesenchymal transition (EMT) inhibition by SFN (2.5 μM, 5 μM, 10 μM) was partly due
to the upregulation of miR‐200c, resulting in the suppression of Cyclooxygenase (COX‐2) and MMP2
and MMP9, which are important for cellular migration [209]. Finally, in prostate cancer, androgen
receptor (AR) activity is important for initiation and progression. In this context, PEITC (10–20 μM)
blocked AR transcriptional activity by decreasing miR‐141 together with increasing miR‐17
expression, followed also by an induction of small heterodimer partner (shp) activity (a repressor of
AR) and suppression of p300/CBP (CREB‐binding protein)‐associated factor (PCAF) (co‐regulator of
AR) respectively [210,211].
1.2.7. Anti‐Angiogenic and Anti‐Metastatic Properties
New vascularization is an important step in tumour progression by supporting increasing
demands for nutrients and oxygen and thus contributes to growth, invasion and metastasis [212].
Metastasis is a complex process, characterized by the loss of cellular adhesion, increased
invasiveness, entry to circulation, colonization and proliferation into new tissue. The metastatic
process is mainly mediated by genes that play an important role in the modification in the interaction
of cells with extracellular matrix and angiogenesis. Among them, MMPs are of significant importance
by mediating the extracellular matrix (ECM) degradation, thus promoting cell migration and
angiogenesis. Although many MMPs are found overexpressed during carcinogenesis and
angiogenesis, MMP‐2 and ‐9 are the most extensively characterized ones [213]. On the other hand,
angiogenesis occurs in six sequential steps, i.e., vascular destabilization, extracellular matrix
degradation, migration and proliferation of endothelial cells, tube formation and vascular
stabilization. The process is regulated by a number of molecules that include MMPs, plasminogen
activators (PAs) and integrins among others. The most studied pro‐angiogenic factor is vascular
endothelial growth factor (VEGF). An imbalance between angiogenic factors and angiogenesis
inhibitors play a pivotal role in carcinogenesis [214,215].
Many studies have tried to elucidate the mechanism of the anti‐angiogenic and anti‐metastatic
capacity of ITCs. In general, it has been proposed that ITCs regulate the expression of important genes
that control a wide range of cellular processes, including cell cycle arrest, cell death, angiogenesis,
cell migration, etc., through modulation of various signalling cascades like p38/MAPK and mTOR
pathways [216–218]. To these ends, exposure of human umbilical vein endothelial (HUVECs) cells to
5 μg/mL AITC and PITC downregulated VEGF and various pro‐inflammatory cytokines (e.g., IL‐1β,
IL‐6, TNF‐alpha), while upregulating IL‐2 and tissue inhibitor of metalloproteinases (TIMP), thus
preventing migration, invasion and tube formation [218]. Similarly, 4 μM PEITC was found to
suppress the secretion of VEGF, downregulate VEGF receptor 2 protein levels and inactivate the
prosurvival serine–threonine kinase Akt, thus preventing new vascularization in HUVECs [219].
BITC, at 2 μM and 5 μM, was also shown to be effective in inhibiting new capillary formation and
invasion of human glioma cells as well as causing G2/M arrest by regulating the expression of
molecules important for cell cycle progression (cyclin B1 and p21) and the neo‐angiogenetic process
(MMPs‐2 and ‐9 and vascular endothelial cadherin (VE‐cadherin). Furthermore, modulation in the
expression of tumour suppressor (miR‐144, miR‐122) as well as oncogenic (miR‐181b, miR‐9) mi‐
RNAs also was observed following the BITC treatment, suggesting involvement of post‐translational
modifications in the anti‐angiogenic properties of BITC [216].
Hypoxia promotes tumour progression, maintenance and metastasis by stimulating
angiogenesis. Thus, hypoxia‐induced angiogenesis is related to hypoxia inducible factor‐1α (HIF‐1α)
expression, which in turn stimulates VEGF‐induced vascular remodelling and is partially regulated
by the mTOR signalling pathway [214,220]. In an experimental setting of hypoxia‐exposed human
colon and gastric cancer cells, exposure to SFN, at concentrations ranging between 12.5 and 50 μM,
dramatically decreased HIF‐1α and VEGF protein levels, as well as hypoxia‐induced migration [221].
Similar results were observed when breast (6.5–26 μM) and renal (5–40 μM) cancer cells were exposed
to PEITC under hypoxic conditions (i.e., suppressing HIF‐1α and VEGF protein levels) [222]. In turn,
VEGF inhibition leads to a decreased expression profile of other proteins also associated with the
vascularisation process. Overall, PEITC‐induced inhibition of angiogenesis was found to be
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PI3K/AKT and ERK/MAPK dependent suggesting an important role of these signalling pathways in
the angiogenetic process [223].
The epithelial‐to‐mesenchymal transition (EMT) is a developmental process of epithelial cell
transformation characterized by loss of polarity and adhesion and an enhancement of migratory and
invasive properties. The process is regulated by various molecules (e.g., E‐cadherin, vimentin,
MMPs) and pathways (e.g., Wnt and Notch) [224,225]. Inhibition of EMT by SFN, in thyroid cancer
cells, has been associated with modulations in the activity of major signalling pathways (PI3K/Akt
and p38/ERK/JNK/MAPK) and depends on ROS production in vitro (20–40 μM) and in vivo (50
mg/kg). Molecules that contribute to EMT process such as E‐cadherin and MMP‐2 and ‐9 were also
downregulated after exposure to SFN [226]. BITC also was able to repress EMT partially through
Forkhead Box Q1 (FOXQ1) suppression in both breast cancer cells (2.5 μM and 5 μM) and xenografts
(7.5 μmol BITC/mouse), thus reducing their metastatic potential [227]. Finally, another study
indicated that VEGF suppression was mediated through inhibition of the Forkhead Box O1
(FOXO1)/AKT pathway as well [228]. In another set of experiments, the anti‐metastatic potential of
AITC (5 μM and 10 μM) was evident after inactivation of the MAPK signalling pathway and
downregulation of MMPs‐2 and ‐9 in human colorectal adenocarcinoma (HT‐29) cells [217].
Furthermore, exposure of these cells to 0.01–10 μM BITC inhibited their growth in a dose‐dependent
manner and altered their metastatic potential by reducing the expression levels of MMP2 and MMP9
and (urokinase‐type plasminogen activator (u‐PA) [229]. On the other hand, 10–15 μM SFN was also
shown to act as an anti‐angiogenic agent through its capacity to supress endothelial cell proliferation,
impair cellular microtubule polymerization and decrease the expression levels of various metastatic
markers (e.g., HIF1α, MMP‐2, VEGF) in human endothelial cells [230,231]. In vivo studies, utilizing
Balb/C mice implanted with VEGF‐impregnated matrigel plugs, further support the anti‐angiogenic
activity of SFN (100 nmol/day, intravenously for seven days) since it decreased VEGF‐induced
vascularization [230].
2. ITCs as Cancer Chemo‐Preventive and Chemo‐Therapeutic Agents
2.1. ITCs as Cancer Chemo‐Preventive Agents: Human Studies
Over the last decades, ITCs have raised scientific interest as agents capable of preventing cancer
development [63,232–237], though such protective effects might depend on the individual’s genetic
variation in (glutathione S –transferase) GST genes, given their important role in the metabolism and
excretion of ITCs as well as in the inactivation of xenobiotics [238–240]. Thus, a reduced activity of
these enzymes is associated with a longer exposure of tissues to ITCs, which significantly decreases
the risk of disease. Therefore, people with inherited two null variants of the glutathione S‐transferase
Mu 1 (GSTM1) and glutathione S‐transferase theta 1 (GSTT1) alleles are more resistant to cancer
development due to longer exposure to ITCs [241–243]. However, current studies support the
association between GST‐null polymorphism with an increased risk of cancer [244–246] while others
suggest that there is no association between cancer risk and GSTs polymorphisms [247,248].
Consequently, it is obvious that the influence of GST genotype on cancer susceptibility is still ill
defined as a result of many inconsistent and contradictory studies in this field of research.
However, epidemiological evidence supports the hypothesis that a diet high in cruciferous
vegetables can gradually reduce the risk of cancer development. An inverse correlation between
cruciferous vegetables consumption and risk of pancreatic cancer was reported in a case‐control
study that included 390 prostate cancer cases and 414 controls in urban Shanghai [249]. In another
case‐control study, a protective effect of cruciferous vegetable consumption was documented against
colorectal cancer risk in women from Shanghai (322 cases and 1251 controls), which was associated
with GSTM1‐ and GSTT1‐null polymorphisms [250]. A study by Zhao et al., 2007 also showed that a
diet rich in cruciferous vegetables decreased the risk of bladder cancer development. In this case‐
control study, 694 newly diagnosed patients and 708 controls participated and found that the highest
consumption of cruciferous vegetables was related to a 29% decreased risk for bladder cancer
development [239]. Furthermore, in another case‐control study of 1619 prostate cancer patients and
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1618 controls (African‐Americans, Caucasian, Japanese and Chinese men), it was shown that an
inverse association exists between cruciferous vegetable consumption and prostate cancer
development [251]. Other case‐control studies have shown that higher dietary intakes of cruciferous
vegetables can decrease the risk of lung cancer, especially squamous and small cell lung carcinomas
[252]. For instance, a case‐control study of 420 Chinese women showed that a diet rich in ITCs led to
a decreased rate of lung cancer incidence, especially in smokers [243]. Moreover, a 32% reduction in
the risk of lung cancer was observed in individuals who consumed three or more weekly servings of
cruciferous vegetables compared to those consuming one‐half servings or less (meta‐analysis of β‐
carotene and retinol efficacy trial (CARET) trial conducted in 14,120 participants) [253]. Several other
case‐control studies also support a beneficial effect of dietary ITCs in breast cancer. More specifically,
studies in Caucasian (740 cases and 810 controls) and Chinese (337 cases and 337 controls) women
found that cruciferous vegetables intake was significantly lower in women diagnosed with breast
cancer than women in control groups [254,255]. Finally, there are several more case‐control studies
associated with low intake of cruciferous vegetables and higher risk of developing various types of
cancer [256–258]. On the other hand, no significant association was observed between cruciferous
vegetable consumption and risk for liver cancer in a study of 217 patients and 42 corresponding
controls in Shanghai [259]. In addition, no significant association was reported between low
cruciferous vegetable consumption and lung cancer susceptibility among smoking women (209
incident lung cancer cases and 787 individually matched non‐smoking controls) although a meta‐
analysis showed an association between urinary ITC levels, GSTM1 genotype and lung cancer risk
[260]. These observations contradict with previous studies, although the majority of research
outcomes suggest that there is an inverse relationship between intake of ITCs derived from
cruciferous vegetables and the overall incidence for various types of cancer development.
2.2. ITCs as Cancer Chemo‐Therapeutic Agents: Animal Studies
2.2.1. In Vitro Studies Utilizing Various ITCs
In a human breast adenocarcinoma cell model, exposure of cells to AITC (5, 10, 15 and 20 μM)
induced generation of oxidative stress as well as the ERK signalling pathway, both of which resulted
in activation of apoptosis (e.g., increased expression of caspase‐3 and ‐9), growth arrest of cells in the
G2/M phase (e.g., increased expression of p21 and suppression of cyclin B and CDK1), mitochondrial
depolarization and deregulation of mitochondrial‐associated proteins (e.g., decreased expression of
Bcl‐2 and increased expression of cytochrome c and Apaf‐1) [111]. In line with these observations, a
study by Wu et al., 2011 reported elevated ROS levels that led to an increase in nitric oxide (NO)
production, deregulation of mitochondria potential, cell cycle suppression and apoptosis in
osteogenic sarcoma cells exposed to BITC (7.5 μM) and PEITC (10 μM) [261]. In a breast cancer cell
model consisting of MDA‐MB‐231 and MCF‐7 cells, exposure of cells to BITC (2.5–20 μM) resulted in
a significant decrease of cell viability mediated by ROS production, mitochondrial dysfunction,
deregulation of pro‐ and anti‐apoptotic genes and activation of various caspases [262]. In addition,
PEITC (0.5–5 μM) was found to be an effective inhibitor of oral squamous carcinoma cell growth
through cell cycle arrest and mitochondrial‐dependent apoptosis due to ROS production and Ca2+
accumulation [96]. On the other hand, AITC (1–40 μM) induced a dose‐dependent inhibition of the
survival of human A549 and H1299 non‐small cell lung cancer (NSCLC) cells by inducing replication
stress as well as sensitizing tumour cells to radiation [263]. Moreover, it has been shown that even
low doses of PEITC (0.1–10 μM) were able to block cell growth and proliferation of prostate cancer
(LNCaP) cells [264]. Finally, exposure of human colon cancer cell lines to SFN and PEITC (0.1–100
μM) have led to a dose‐dependent inhibition of their proliferation as well as apoptotic induction
[265].
Exposure to PHI (5–40 μM) blocked cell cycle progression in human leukaemia cells through
perturbations in acetylated as well as methylated states of chromatin histones [266]. In comparison,
in human embryonic kidney 293 cells and human colorectal cancer (HCT116) cells, exposure to SFN
(15 μM) caused a decrease in HDAC‐3 and ‐6 activity levels while raising p21 expression levels
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suggesting that SFN could act as an effective tumour‐suppressor agent [188,267]. SFN (15 μM) was
also found to be an efficient HDAC inhibitor in BPH‐1, LnCaP and PC‐3 prostate epithelial cells
resulting in triggering of growth arrest and induction of the apoptotic process as well [183].
Furthermore, in prostate cancer, GSTP1 methylation is known to play an important role in tumour
initiation. In this context, PEITC (0.5–20 μM) was found to suppress the deacetylation and
methylation of the GSTP1 gene and thus block the carcinogenic process [268].
Exposure of prostate cancer cells to PEITC (5 μM and 7.5 μM) and SFN (20 μM and 30 μM)
significantly inhibited phosphorylation of IKK/IκB kinases and p65 as well as NFκB subunit nuclear
translocation, thus suppressing the expression of NFκB‐related genes (e.g., VEGF, cylcin D1 and B‐
cell lymphoma‐extra large (Bcl‐XL) leading to disturbing angiogenesis and invasion [269].
Alternatively, the signal transducer and activator of transcription 3 (STAT3) factor is found to be
overexpressed in various cancers where it favours tumour growth and progression. A study by
Boreddy et al., 2011 has shown that BITC (5–20 μM) inhibited the phosphorylation of STAT3 in
pancreatic cancer cell lines followed by a decrease in VEGF and MMP‐2 expression, thus blocking
angiogenesis [270].
In addition, it was proposed that ITCs protect against tumourigenesis by enhancing the
ubiquitination process of oncogenes, thus favouring their degradation by the proteasome. In fact,
both BITC and PEITC have been shown to target USP9x (ubiquitin specific peptidase 9 X‐linked), a
member of deubiquitinating enzymes (DUB), thus promoting the anti‐apoptotic protein Mcl‐1
(myeloid cell leukaemia‐1) and the oncogenic fusion protein Bcr‐Abl for degradation in various
tumourigenic cell lines [271]. Finally, another target of ITCs’ anti‐proliferative effect is tubulin, which
is known to disrupt microtubule polymerization and, consequently, induce mitotic arrest and
apoptosis [272–274]. Thus, it becomes evident that a number of studies support the plurality of effects
of ITCs in various cancers including ovarian [275], glioma [276], bladder [277], breast [278,279],
myeloma [280], prostate [281–283] and colon [284].
2.2.2. In Vivo Studies Utilizing Various ITCs
Oral administration of AITC in the form of mustard seed powder (9 μmol/kg or 90 μmol/kg body
weight, once daily for three weeks) significantly prevented tumour development in mouse bladders
and invasion in muscles by triggering cell cycle arrest and apoptosis while inhibiting angiogenesis
[285]. At the same time, BITC (5 mg/kg and 10 mg/kg body weight, every day for 19 weeks)
suppressed the development of prostate cancer in a transgenic mouse adenocarcinoma model by
inducing cell cycle arrest. Moreover, BITC resulted in reduced Ki67 (a proliferation marker), cyclin
A, cyclin D1 and CDK2 expression in the prostatic tissue [286]. A study by Srivastava et al., 2003 also
demonstrated that injection of 10 μM AITC three times per week significantly inhibited the growth
of PC‐3 xenografts in vivo by inducing apoptosis, thereby decreasing the proportion of cells
undergoing mitosis [287]. SFN (at an average daily dose of 7.5 μmol per animal for 21 days) also
decreased prostate cancer cell proliferation in xenografts by suppressing HDAC activity. A reduction
in HDAC activity was also observed in the peripheral blood mononuclear cells of healthy humans
after consumption of broccoli sprouts (a single dose of 68 g broccoli sprouts, approximately 105 mg
SFN; equivalent to approximately 570 g of mature broccoli) [288]. Intraperitoneal administration of
SFN in nude mice (25 mg/kg, 50 mg/kg or 100 mg/kg, 3 times/week) injected with lung
adenocarcinoma (LTEP‐A2) cells significantly decreased cell proliferation and thus tumour
progression [289]. Moreover, 5 μM SFN and PEITC found to significantly reduce the formation of
colonic aberrant and multicrypt foci in F344 rats [290]. Also, mice inoculated with pancreatic cancer
(BxPC‐3) cells and then orally treated with 12 μM BITC showed 43% less tumour growth (in
comparison to control mice) through repression of PI3K, AKT, PDK1, mTOR, FOXO1 and FOXO3a,
in addition to an increased apoptotic induction [291].
On another note, a study by Xu et al., 2006 also described that topical application of 100 nmol of
SFN once a day was capable of suppressing 7,12‐dimethylbenz(a)anthracene (DMBA) / 12‐O‐
tetradecanoylphorbol‐13‐acetate (TPA)‐induced skin tumourigenesis, in C57BL/6 mice, an effect
which was mediated by Nrf2 [292]. Microarray‐based identification of gene expression patterns in

Antioxidants 2019, 8, 106

15 of 32

the liver of both wild‐type and Nrf2 knock‐out C57BL/6J mice exposed to SFN (90 mg/kg
administered orally) revealed that SFN induced Nrf2 activity. This, in turn, regulates the expression
of various other proteins, like phase II detoxifying enzymes (e.g., HO‐1, GSTs), cell cycle and growth
associated proteins (cyclins, growth factors), heat‐shock proteins (e.g., Hsp90) and various kinases
(e.g., PI3K, MEKs) thus confirming previous observations on ITC‐induced Nrf2 activity [293]. PEITC
(12 μmol/day, 5 days/week) was also found to inhibit tumour formation in human pancreatic cancer
(MIAPaca2) cell line xenograft mice [120]. In bladder cancer, both SFN and ECN (295 μmol/kg orally
once a day) were found to significantly block HDAC activation in vivo [184].
Finally, the anti‐angiogenic and anti‐metastatic effects of ITCs have been also demonstrated in
vivo. More specifically, oral administration of 12 μM BITC suppressed new vessel formation and
suppressed pancreatic tumour growth in mice through inhibition of STAT3 phosphorylation. The
tumours collected from mice were characterized by decreased expression of angiogenesis‐related
proteins, including HIF‐α, VEGF, MMP‐2 [270]. On the other hand, oral administration of 10 μM
PEITC in MDA‐MB‐231‐BR xenografts prevented the growth of tumour and enhanced the survival
of xenografts compared to controls, while the expression levels of VEGF were downregulated in the
tumour‐bearing mice [294]. In addition, oral administration of 50 μmol/kg or 150 μmol/kg of PEITC
inhibited capillary formation and attenuated tumour invasiveness in a chemically induced murine
breast cancer model [295].
3. ITCs as Anti‐Melanoma Agents
Malignant melanoma is a highly aggressive and metastatic type of skin cancer with adverse
prognosis, high mortality rates and a poor response to current therapeutic strategies. Its incidence is
multifactorial. The most important risk factor for melanoma development is exposure to UV
(ultraviolet) radiation by means of prolonged exposure to solar energy and/or frequent use of tanning
beds. Other factors that increase the likelihood of disease development include innate predisposition
and inheritable traits including fair skin, sun sensitivity and/or a large number of moles [296]. The
aggressive nature of melanoma is associated with the accumulation of mutations that activate
oncogenes (e.g., BRAF, NRAS), while inactivating tumour suppressor genes (e.g., phosphatase and
tensin homolog; PTEN) [297]. Overall, the molecular pathways that regulate the expression of these
genes are constituently activated in melanoma. More specifically, the most important pathways
found to be overexpressed include p38/JNK/ERK/MAPK, PI3Kinase/Akt/mTor, β‐catenin and Wnt.
Deregulation of proteins important for cell cycle progression and apoptosis also account for the
increased survival and proliferation of melanoma cells. Anti‐apoptotic proteins such as Bcl‐2 and Bcl‐
xL are overexpressed, while pro‐apoptotic modulators such as Bax, Apaf‐1 and p53 are suppressed
in melanoma. Angiogenesis also plays an important role in melanoma progression and metastasis,
thus molecules capable of targeting genes related to both of these processes may be part of an effective
anti‐melanoma strategy [298,299]. Finally, epigenetic modifications in pathways controlling cell
growth, proliferation, motility and apoptosis have also recently been identified in malignant
melanoma cells [300].
The anti‐carcinogenic effect of ITCs in malignant melanoma has been studied by utilizing both
in vitro and in vivo models. In general, ITCs were found to be able to induce growth arrest and
apoptosis [301] and also inhibit metastasis [302,303] through induction of various signal transduction
pathways, generation of oxidative stress and disruption of mitochondrial function, all of which are
important mediators of cell growth and proliferation [296].
3.1. In Vitro Studies Utilizing Various ITCs
The anti‐melanoma effect of ITCs has been studied by utilizing in vitro models of both human
and murine species. In murine (B16F‐10) melanoma cells, activation of multiple caspases, pro‐ and
anti‐apoptotic proteins and pro‐inflammatory cytokines (e.g., TNF‐α, interleukin‐1β, IL‐6, IL‐12p40
and NF‐κB) were all shown to be involved in SFN‐induced apoptosis (1–5 μM) [304]. Furthermore,
exposure of these cells to 1–5 μg/mL AITC and PITC depleted the expression and secretion of agents
that favour blood vessel formation (e.g., TNF‐α and NO) [305]. Such anti‐angiogenic capacity was
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also exerted by AITC and PITC in B16F‐10 melanoma cells through decreased expression of VEGF at
5 μg/mL [216]. Moreover, the expression of platelet‐activating factor receptor (PAF‐R) is linked to a
higher metastatic potential in melanoma cells. Exposure to 5–50 μM BITC significantly increased
apoptotic cell death in murine PAF‐R positive‐cells in contrast to PAF‐R negative B16F10 cells,
suggesting selectivity of BITC towards PAF‐R, which is promising for a better management of PAF‐
R‐positive melanoma patients. The apoptotic process was found to be mediated by elevated ROS
production and caspase3/7‐like activity [306]. In line, another study by Lai et al., 2017 also supported
the anti‐metastatic potential of BITC and PEITC (1 μM, 2.5 μM and 5 μM) in B16F‐10 cells by showing
that both ITCs decreased cell viability, mobility, migration and invasion via inhibition of MMP‐2
activity and impaired expression of important metastasis‐related proteins like MAPK signalling‐
associated proteins (e.g., p‐ERK1/2, p‐p38 and p‐JNK1/2), RhoA, Ras, SOS‐1, FAK, GRB2, TIMP and
NF‐kB [307]. Similarly, BITC (0.5 μM, 1 μM and 2 μM) and PEITC (1 μM, 2 μM and 2.5 μM) also
prevented human melanoma A375.S2 cell migration and invasion through inhibition of MMP‐2
activity as well as via affecting the MAPK signalling pathway [308]. Treatment with SFN at 20 μM
has been shown to decrease cell survival through activation of p38 and p53, which regulate the
expression of pro‐apoptotic proteins, such as Bak and PUMA, in both Bowes and SK‐Mel‐28 human
melanoma cells [309]. In addition, exposure of human malignant melanoma (A375) cells to 0.1–5 μM
SFN, BITC and PEITC exerted a cytotoxic effect via multiple apoptotic pathways (intrinsic, extrinsic
and endoplasmic reticulum‐based), as shown by the increased activity of various caspases indicative
of such differential activation [310]. A study by Huang et al., 2012 also showed that addition of PEITC
at concentrations of 5–15 μM inhibited the growth of A375.S2 cells by causing G2/M‐dependent cell
cycle arrest and inducing the intrinsic apoptotic pathway through ROS‐mediated mitochondrial
dysfunction [301]. Similarly, exposure of A375.S2 melanoma cells to 5–20 μM BITC decreased cell
growth and survival in a dose‐dependent manner. BITC promoted ROS accumulation in cells and
caused changes in the expression of various cyclins and CDKs (e.g., cyclin A, CDK1, CDC25), proteins
of the B‐cell lymphoma 2 (BCL2) family and various caspases [311]. In line with these observations,
5 μM of SFN, BITC and PEITC have also been documented to induce G2/M cell cycle arrest by
affecting the expression levels of various cell‐cycle regulators in human malignant melanoma (A375)
cells [312]. Moreover, the effect of AITC on lysine acetylation and methylation marks on histones H3
and H4 have been explored recently. To this end, exposure of A375 cells to 10 μM of AITC decreased
HDAC and histone acetyl transferase (HAT) activities, while also affecting the acetylated and
methylated content of histones (by means of assessing specific lysine modifications), suggesting that
AITC can exert an epigenetically‐induced anti‐melanoma activity [313].
ITCs were also found to affect TRPA (transient receptor potential) ion channels in melanoma
cells, which are responsible for calcium efflux in various types of skin cells and are involved in both
physiological (e.g., epidermal homeostasis, sensory function) and pathological (e.g., melanoma)
processes. For example, although TRPM1 (transient receptor potential cation channel subfamily M
member 1) is expressed in melanocytes mediating melanin production in melanoma, TRPA1
promotes tumour progression and invasiveness and is linked to a more aggressive disease phenotype
[314]. Furthermore, TRPA1 was found to be functionally expressed in various human malignant
melanoma cell lines but, at the same time, was not critical for an impaired proliferation caused after
exposure of these cells to AITC (25–400 μM) [315].
On the other hand, oil extracted from the roots and seeds of the plant Eruca sativa (rocket salad;
a member of Cruciferous family) has been reported to exert an anti‐melanoma activity. Exposure of
B16F10 murine and MDA‐MB‐435 human melanoma cell lines to 20–100 μg/mL of the extract (major
components were ECN, SFN, AITC, 3‐butenyl‐ITC and 2‐phenylethyl‐ITC) significantly inhibited cell
proliferation [316]. Also, combinational treatment of AITC, PEITC and SFN (3–50 μM) was found to
be a more potent inhibitor of B16F‐10 proliferation than the seed oil extract itself [317]. Finally, ITCs
decreased proliferation in melanoma stem cells (MSCs), a subgroup of malignant melanoma cells
with high metastatic and invasive capacity. MSCs express Ezh2 polycomb group protein that plays
an important role in cell survival and which was shown to be suppressed after exposure to 1–20 μM
SFN, thereby reducing cell viability, migration and invasion in these cells [318]. However, it was
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recently reported that the various biological effects of SFN can be attenuated from the presence of
other biological factors, in vivo (e.g., the nerve growth factor, etc.), suggesting that a better
understanding in the interaction of these compounds with other elements in the body is crucial in
order to determine their in vivo efficacy [319].
3.2. In Vivo Studies Utilizing Various ITCs
The cytotoxic effect of ITCs has been shown in a number of malignant melanoma animal models.
To this end, a study by Bansal et al., 2015 documented that a combinational treatment consisting of
allyl isothiocyanate, phenylethyl isothiocyanate and sulphoraphane (at 1:1:1 ratio; 10 μM) decreased
tumour growth, volume and weight in C57BL/6 mice injected with B16F‐10 melanoma cells and that
such a combination was more potent than treatment with naturally occurring Eruca sativa seed oil
alone [320]. Intraperitoneal injection of 20 mg/kg and 40 mg/kg PEITC as well as 20 mg/kg BITC
significantly decreased the size and weight of tumours in BALB/c mice injected with A375.S2 cells,
suggesting that both agents can be effective in melanoma chemotherapy [321,322]. The anti‐
metastatic potential of both AITC and PEITC has been shown to be linked with inhibition of
angiogenesis. More specifically, in C57BL/6 mice inoculated with B16F‐10 melanoma cells, capillary
formation was prevented after exposure to AITC and PITC (25 μg/dose/animal/day), an effect which
was mediated by reduction in the expression levels of NO and TNF‐α, both of which promote
capillary formation [305]. In another study, exposure to AITC and PITC intraperitoneally at a dose of
1.1 mg/kg also inhibited the B16F‐10‐induced metastasis in the lungs of C57BL/6 mice [323]. In line
with these observations, SFN (administered intraperitoneally at a dose of 500 μg/dose/animal/day)
also blocked the metastatic potential of B16F‐10 cells inoculated in C57BL/6 by inducing a cell‐
mediated immune response and triggering the expression of IL‐2 and IFN‐gamma, while suppressing
those of IL‐1beta, IL‐6, TNF‐alpha and GM‐CSF (granulocyte‐macrophage colony‐stimulating factor)
[324]. Moreover, SFN (3.5 mg/kg body weight, injected thrice a week) inhibited cell proliferation and
migration in B16F10 xenografts, effects which were both mediated by a reduction in the expression
levels of MMP‐9 [325]. Additionally, ITCs were also shown to play a role in melanoma epigenetic
therapy. More specifically, SFN inhibited growth and proliferation of B16 and S91 murine melanoma
cells by downregulating deacetylation enzymes and intraperitoneal injections of SFN‐encapsulated
microspheres (500 μmol/kg) enhanced its anti‐cancer activity in melanoma tumour‐bearing C57BL/6
mice [326]. Also, the effect of SFN in Ezh2 stem cell survival protein was assessed after oral
administration in mice inoculated with A375 melanoma cancer stem cell (MCS) cells. SFN (10
μmol/kg body weight; three times per week) inhibited tumour growth, an effect which was associated
with reduced expression levels of matrix metalloproteinases, increased expression levels of TIMP3
(Metalloproteinase inhibitor 3) and enhanced apoptosis [318]. Based on our current knowledge of
ITCs’ effectiveness in melanoma prevention, synthetic analogues (with longer side chains with
selenium substituting the sulphur group) have been produced and shown to be effective in inhibiting
melanoma survival by regulating signalling pathways like the Akt3 pathway, but without affecting
normal cells [327–329]. For instance, naphthalimide is one such ITC synthetic analogue that has been
found to exert cytotoxicity in both in vivo and in vitro experimental settings [330].
4. Conclusions
ITCs are potent electrophiles derived from the breakdown process of GLs, which are abundant
in cruciferous vegetables. They are currently considered as an important class of nutraceuticals,
characterized by a wide range of properties (e.g., anti‐bacterial, anti‐inflammatory, anti‐cancer)
suggesting their possible use in various industries ranging from food to medicine to clinical practice.
Their potential application in cancer prevention strategies have posed greater interest over the last
years. According to various studies, the consumption of cruciferous vegetables has been associated
with a reduced risk of cancer development, thus supporting their protective role. In addition to their
protective role, a large body of evidence shows the anti‐tumourigenic action of ITCs against different
types of cancer both in vitro and in vivo. The observed tumour‐inhibitory effects of ITCs have been
shown to be mediated through modulation of various cancer‐related critical pathways (e.g.,
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enzymatic detoxification, apoptotic induction, oxidative stress generation, signal transduction,
epigenetic induction, etc.) and they seem to be more potent against cancer than normal cells. The
most important and well characterized pathway associated with the protective effect of ITCs is the
Nrf2 pathway, which is associated with the detoxification and elimination of carcinogens from the
body. However, various studies have shown its constitutive expression could lead to resistance in
chemotherapy. Despite that fact, the overwhelming majority of studies support the protective role of
these agents which (together with their low toxicity profile) makes them excellent chemotherapeutic
candidates against tumour initiation and progression. However, further studies are needed in order
to determine the optimum dose‐response and time‐course of ITCs, as these parameters can be a
significant limitation for their long‐term usage in cancer therapeutic interventions.
Melanoma is a highly aggressive type of skin cancer being linked with high mortality rates due
to its high metastatic potential and treatment resistance. As such, the disease does not always respond
to current therapeutic approaches, largely due to the development of multi‐drug resistance. Thus, it
is imperative that new potent chemotherapeutic agents are developed for disease management. To
this end, ITCs have been studied for their anti‐melanoma efficacy by means of interfering with
various pathways including inhibition of cell growth and proliferation in both in vitro and in vivo
experimental models.
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